Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Sonelokimab Promising for Patients with PsA

  |  

The 60 mg dose of sonelokimab was adequate to reach high levels of response in the general trial population. However, the 120 mg dose of sonelokimab was found to further improve responses in specific patient subgroups. Therefore, it’s anticipated both doses will be investigated in phase 3 clinical trials.

The discontinuation rates were low (~5%), and the safety profile of sonelokimab was consistent with previous studies. No new safety signals were identified.

ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. MoonLake announces significant improvements with nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day [news release]. MoonLake Immunotherapeutics. 2024 Mar 10.
  2. Evaluation of sonelokimab for the treatment of patients with active psoriatic arthritis [NCT05640245]. ClinicalTrials.gov. 2024 Apr 25.
  3. Jin B-K, Odongo S, Radwanska M, et al. Nanobodies: A review of generation, diagnostics and therapeutics. Int J Mol Sci. 2023:24:5994.
  4. Sanofi’s Cablivi (caplacizumab-yhdp): A new era in acquired thrombotic thrombocytopenic purpura (aTTP) treatment [news release]. Sanofi. 2019 Feb 6.

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    The Latest Psoriatic Arthritis Management Insights

    An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater…